Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 2/20 | 0.59 |
| ▸ | TRPV1 | Q8NER1 | 6/20 | 0.55 |
| ▸ | BRAF | P15056 | 7/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.51 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.51 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.51 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.51 |
| ▸ | KDR | P35968 | 2/20 | 0.49 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.48 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14084105 | 0.94 | TRPV1 (0.60) | GRM4TRPV1BRAFLMNAGAA | |
| SCHEMBL14083101 | 0.89 | MAPT (0.57) | GRM4TRPV1BRAFLMNAGAA | |
| SCHEMBL14083721 | 0.89 | TRPV1 (0.50) | GRM4TRPV1BRAFLMNAGAA | |
| SCHEMBL14083663 | 0.88 | TRPV1 (0.72) | TRPV1KCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL14083759 | 0.87 | MAPT (0.63) | GRM4TRPV1BRAFLMNAGAA | |
| SCHEMBL14083716 | 0.86 | KCNQ3 (0.57) | TRPV1RAB9AKCNQ3KCNQ2KCNE1 | |
| SCHEMBL14083712 | 0.86 | TRPV1 (0.58) | TRPV1BRAFMAPTKCNQ3KCNQ2 | |
| SCHEMBL14083256 | 0.85 | TRPV1 (0.62) | GRM4TRPV1BRAFLMNAGAA | |
| SCHEMBL14083484 | 0.85 | TRPV1 (0.76) | GRM4TRPV1BRAFLMNAGAA | |
| SCHEMBL14083635 | 0.85 | TRPV1 (0.56) | TRPV1KCNQ3KCNQ2KCNE1KCNQ1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200524-A1 | Amide compounds as ion channel ligands and uses thereof | KELLY MICHAEL G | 2008-08-21 | — | — | US | disclosed |
| US-20080200524-A1 | Amide compounds as ion channel ligands and uses thereof | KELLY MICHAEL G | 2008-08-21 | — | — | US | disclosed |
| US-7338950-B2 | Amide compounds as ion channel ligands and uses thereof | RENOVIS, INC. (US) | 2008-03-04 | — | — | US | disclosed |
| US-7338950-B2 | Amide compounds as ion channel ligands and uses thereof | RENOVIS, INC. (US) | 2008-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200524-A1 | Amide compounds as ion channel ligands and uses thereof | TRPV1, TRPA1, TRPV2 | GRM4 362/4885TRPV1 1/4885BRAF 2897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.